Sinclair, Jonathan Kenneth ORCID: 0000-0002-2231-3732, Du, XuanYi, Shadwell, Gareth, Dillon, Stephanie
ORCID: 0000-0002-3369-8199, Butters, Bobbie
ORCID: 0000-0002-8666-4259 and Bottoms, Lindsay
(2025)
Effects of Peppermint (Mentha piperita L.) Oil in Cardiometabolic Outcomes in participants with pre and stage 1 hypertension: Protocol for a Placebo Randomized Controlled Trial.
PLOS ONE
.
Preview |
PDF (AAM)
- Accepted Version
Available under License Creative Commons Attribution. 758kB |
Official URL: https://journals.plos.org/plosone/
Abstract
Background
Hypertension is the predominant risk factor for cardiovascular disease morbidity and mortality, with significant healthcare utilization and expenditure. Pharmaceutical management is habitually adopted; although its long-term effectiveness remains ambiguous, and accompanying adverse effects are disquieting. Peppermint owing to its abundance of menthol and flavonoids, possesses a range of potential hypertensive benefits.
Rationale:
Our previous trial has shown that peppermint is able to mediate significant improvements in systolic blood pressure in healthy individuals. But there has yet to be any randomized placebo-controlled studies, examining the efficacy of peppermint supplementation in hypertensive individuals
Objective: This study proposes a placebo randomized controlled trial, exploring the effects of daily peppermint oil supplementation on outcomes pertinent to hypertensive disease in individuals with pre and stage 1 hypertension.
Methods and analyses:
This 20-day, parallel randomized, placebo-controlled trial will recruit 40 individuals, assigned to receive either 100μL per day of either Peppermint oil or a peppermint flavoured placebo. The primary trial outcome will be the between-group difference in systolic blood pressure from baseline to post-intervention. Secondary outcome measurements will be between-group differences in anthropometric, haematological, diastolic blood pressure/ resting heart rate, psychological wellbeing, and sleep efficacy indices. Statistical analysis will be conducted on an intention-to-treat basis using linear mixed effects models to contrast differences in the changes from baseline to 20-days between the two trial arms.
Ethics and dissemination:
Ethical approval has been granted by the University of Central Lancashire (HEALTH 01074) and the study has formally been registered as a trial (NCT05561543). Dissemination of the trial findings will be through publication in a peer-reviewed journal.
Trial registration: ClinicalTrials.gov NCT05561543
Ethics: HEALTH 01074
Repository Staff Only: item control page